Document Detail

The influence of renal and cardiovascular abnormalities on blood pressure in Turner syndrome.
MedLine Citation:
PMID:  10718836     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Patients with Turner syndrome (TS) are at an increased risk of morbidity and mortality from cardiovascular disease. This study was undertaken to establish the prevalence of hypertension in patients with TS and to establish to what extent cardiovascular or renal abnormalities contribute to the measured blood pressure. PATIENTS AND METHODS: 62 patients with TS, age 5.4-22.4 years, had 24 h-ABPM (ambulatory blood pressure monitoring), echocardiography, renal imaging and measurement of recumbent plasma renin activity (PRA). Blood pressure was compared with population standards. RESULTS: 21% of the TS study population had mean systolic and 17% mean diastolic 24 h-ABPM measurements above the 95th percentile for age and sex (i.e. mild hypertension). Borderline blood pressure (i.e. 90th to 95th percentile) was found in another 17% of the patients. 57% of the patients had a blunted (i.e. less than 10%) fall in the night-time blood pressure. 24% of the patients had a detectable cardiac abnormality, 42% a detectable renal abnormality and 52% were found to have raised plasma renin activity. The presence of a cardiac or renal abnormality had no significant effect on blood pressure. Blood pressure of patients on growth and/or pubertal therapy was not different from those patients on no such treatment. CONCLUSION: Over 30% of patients with Turner syndrome were found to be mildly hypertensive and over 50% had an abnormal diurnal blood pressure profile. In this study we were unable to demonstrate that the presence of renal or cardiac abnormalities had an effect on recorded blood pressure. The use of growth hormone and oestrogen to manage growth failure and pubertal delay did not seem to affect blood pressure. This study suggests that there is a high prevalence of raised blood pressure in Turner syndrome patients. The 24 h-ambulatory blood pressure monitoring profile suggests that this may be secondary in origin, but we were unable to demonstrate an underlying mechanism with the renal and cardiac investigations performed.
N C Nathwani; R Unwin; C G Brook; P C Hindmarsh
Related Documents :
18849386 - Roles of eating, rumination, and arterial pressure in determination of the circadian rh...
2327926 - Intra-abdominal pressure and renal function after surgery to the abdominal aorta.
1871796 - Progression of kidney disease in chronic renal transplant rejection.
17762656 - Renal angioplasty causes a rapid transient increase in inflammatory biomarkers, but red...
12098646 - The formation and circulation of cerebrospinal fluid inside the cat brain ventricles: a...
10867166 - Influence of sex and age on blood pressure variability.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical endocrinology     Volume:  52     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2000 Mar 
Date Detail:
Created Date:  2000-05-15     Completed Date:  2000-05-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  371-7     Citation Subset:  IM    
The London Centre for Paediatric Endocrinology, University College London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anabolic Agents / therapeutic use
Analysis of Variance
Blood Pressure Monitoring, Ambulatory
Child, Preschool
Cross-Sectional Studies
Drug Therapy, Combination
Ethinyl Estradiol / therapeutic use
Growth Hormone / therapeutic use
Heart Defects, Congenital / complications*,  physiopathology
Hypertension / etiology*,  physiopathology
Kidney / abnormalities,  physiopathology
Oxandrolone / therapeutic use
Progesterone / therapeutic use
Renin / blood
Turner Syndrome / complications*,  physiopathology
Reg. No./Substance:
0/Anabolic Agents; 53-39-4/Oxandrolone; 57-63-6/Ethinyl Estradiol; 57-83-0/Progesterone; 9002-72-6/Growth Hormone; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Blood pressure and Turner syndrome.
Next Document:  Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination...